Showing results (851-860 of 955) with videos related to
Sort By:
Pageof 96
Bioorganic & Medicinal Chemistry Letters|March 25, 2018
Sulfoximines as potent RORγ inverse agonistsGilles Ouvry, Franck Bihl, Claire Bouix-Peter, et al.Physical Review Letters|April 17, 2002
JET quasistationary internal-transport-barrier operation with active control of the pressure profileF Crisanti, X Litaudon, J Mailloux, et al.European Journal of Cancer (Oxford, England : 1990)|March 29, 2021
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov studySylvain Ladoire, Vincent Goussot, Emilie Redersdorff, et al.European Journal of Cancer (Oxford, England : 1990)|February 21, 2022
Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional studySylvain Ladoire, Emilie Rederstorff, Vincent Goussot, et al.Journal of Gastrointestinal Oncology|May 18, 2023
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinomaDavid Piquemal, Roman Bruno, Barbara Bournet, et al.Journal of Extracellular Vesicles|June 30, 2020
Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot studyGaëtan Chanteloup, Marine Cordonnier, Nicolas Isambert, et al.BMC Genomics|September 17, 2013
Comparative genomics of emerging pathogens in the Candida glabrata cladeToni Gabaldón, Tiphaine Martin, Marina Marcet-Houben, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 StudyErika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, et al.Cancer Research|May 19, 2005
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerStephen R Wedge, Jane Kendrew, Laurent F Hennequin, et al.Journal of Medicinal Chemistry|April 13, 2018
Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory AcneJean-François Fournier, Laurence Clary, Sandrine Chambon, et al.Pageof 96